李志剛,男,主任醫(yī)師,博導(dǎo),醫(yī)學(xué)博士。
上海市胸科醫(yī)院胸外科
美國胸外科協(xié)會Evarts A. Graham Fellow(2011-2012)
上海市”東方英才”領(lǐng)軍人才
上海工匠
2011年獲得國際胸外科界最為重要的人才培養(yǎng)計劃-美國胸外協(xié)會每年1名的Graham Fellow培訓(xùn)機會,在北美最重要的5所胸外科醫(yī)療中心進行了系統(tǒng)的科研、臨床培訓(xùn)。2014年任上海市胸科醫(yī)院胸外科副主任,2015年兼任食管外科主任,成功帶領(lǐng)團隊打造了國內(nèi)最大的疑難復(fù)雜食管疾病診療中心,建成“一站式”食管疾病臨床診療平臺—包括機器人輔助微創(chuàng)外科、放化/免疫治療的食管癌綜合診療體系及磁力環(huán)抗胃食管反流病良性疾病的技術(shù)獨創(chuàng)。在高水平學(xué)術(shù)期刊包括Cancer Cell (2023), J Immunother Cancer (2022), Nat Commun (2021), Ann Surg (2021), JTCVS (2023)等發(fā)表SCI論文63篇,牽頭開展多項重要臨床試驗,主持1項科技部重點研發(fā)課題、1項國自然基金國際重點項目、3項國自然基金面上項目以及多項市級/校級項目,當(dāng)選上海市優(yōu)秀學(xué)術(shù)帶頭人及上海市領(lǐng)軍人才。
社會任職
上海醫(yī)師協(xié)會胸外科分會副會長 食管學(xué)組組長
· 中國醫(yī)師協(xié)會胸外科分會 食管學(xué)組副組長
· 中國醫(yī)學(xué)裝備協(xié)會智能裝備技術(shù)分會常委
· 中國抗癌協(xié)會(CACA)食管癌專業(yè)委員會委員
· 中國醫(yī)師協(xié)會內(nèi)鏡醫(yī)師分會委員
· 中華醫(yī)學(xué)會胸心血管外科分會食管學(xué)組委員
· 中國臨床腫瘤學(xué)會(CSCO)食管癌專業(yè)委員會委員
· 中國醫(yī)促會胃食管反流多學(xué)科分會 副主任委員
· 中華消化外科菁英薈 食管學(xué)組 組長
· 美國胸外科協(xié)會(AATS)會員
· 世界食管疾病協(xié)會(ISDE)會員
獲獎榮譽
. 2023年上海工匠
· 2023年上海醫(yī)務(wù)工匠
· 2022年上海市胸科醫(yī)院“院長獎”
· 2022年上海市領(lǐng)軍人才
· 2022年上海市優(yōu)秀學(xué)術(shù)帶頭人
· 2022年上海交通大學(xué)醫(yī)學(xué)院附屬醫(yī)院“杰出帶教老師獎”
· 2021年上海市胸科醫(yī)院“院長獎”提名
· 2015年上海市科技進步獎三等獎(食管癌規(guī)范化外科治療模式與應(yīng)用,排名3/5)
· 2011年美國胸外科協(xié)會 AATS Graham Fellowship (每年全球1名)
科研成果
1) 國家自然科學(xué)基金重點國際(地區(qū))合作研究項目,82320108016,食管癌新輔助治療中靶向化療耐藥改善免疫治療抵抗的機制發(fā)現(xiàn)和功能解析,2024-01至2028-12,210萬元,在研,主持
2) 國家重點研發(fā)計劃,2021YFC2501005,食管癌變動態(tài)演進機制及個體化精準診療體系構(gòu)建研究,2021-12至2024-12,450萬元,在研,主持
3) 國家自然科學(xué)基金面上項目,82172756,表達CCL5/IL-15雙因子的溶瘤腺病毒協(xié)同增效食管癌免疫綜合治療的機制研究,2022-01至2025-12,55萬元,在研,主持
4) 上海東方英才計劃領(lǐng)軍項目,食管外科精準診療關(guān)鍵技術(shù)創(chuàng)新與體系構(gòu)建,2024-01至2028-12,80萬元,在研,主持
5) 上海市優(yōu)秀學(xué)術(shù)帶頭人,22XD1402900,食管癌分層治療及預(yù)后評價體系的創(chuàng)新及推廣應(yīng)用,2022-09至2025-08,40萬元,在研,主持
6) 上海申康醫(yī)院發(fā)展中心,第二輪《促進市級醫(yī)院臨床技能與臨床創(chuàng)新三年行動計劃》關(guān)鍵支撐項目,SHDC2020CR6002,上海市食管癌特色專病隊列數(shù)據(jù)庫,2020-12至2022-09,387萬元,已結(jié)題,主持
7) 上海交通大學(xué)附屬胸科醫(yī)院,多學(xué)科協(xié)同創(chuàng)新重點培育項目,YJXT20190202,食管鱗癌新輔助放化療后臨床模塊化檢查評估診斷試驗(Pre-SINO試驗),2019-01至2021-12,100萬元,已結(jié)題,主持
8) 上海交通大學(xué)醫(yī)學(xué)院,雙百人項目,粘膜下(T1b)食管鱗癌保留食管的非手術(shù)治療模式探索,2018-10至2024-10,200萬元,在研,主持
9) 上海申康醫(yī)院發(fā)展中心臨床診療技術(shù)示范應(yīng)用的規(guī)范化管理研究項目,食管癌的綜合診治路徑SOP,SMIDF81B,2022-11至2023-03,5萬元,在研,主持
10) 上海交通大學(xué),轉(zhuǎn)化醫(yī)學(xué)協(xié)同創(chuàng)新中心合作研究項目,TM201823,吲哚箐綠熒光示蹤探查食管癌前哨淋巴結(jié),2018-08至2020-07,8萬元,已結(jié)題,主持
11) 上海申康醫(yī)院發(fā)展中心,第一輪《促進市級醫(yī)院臨床技能與臨床創(chuàng)新三年行動計劃》,16CR1035B,機器人輔助下胸、腹腔鏡與傳統(tǒng)胸、腹腔鏡微創(chuàng)治療食管鱗癌的前瞻性、多中心、開放、隨機對照研究,2017-01至2019-12,150萬元,已結(jié)題,主持
12) 國家自然科學(xué)基金面上項目,81372472,OCT4調(diào)控Survivin促進食管癌增殖的分子機制及干預(yù)策略,2014-01至2017-12,75萬元,已結(jié)題,主持
13) 上海市科學(xué)技術(shù)委員會,科研計劃項目,134119a7200,淺表型食管癌的內(nèi)外科微創(chuàng)治療及預(yù)后影響因素,2013-09至2016-09,10萬元,已結(jié)題,主持
14) 國家自然科學(xué)基金面上項目,30973469,食管癌高特異性免疫細胞治療疫苗的創(chuàng)制及其實驗研究,2010-01至2012-12,31萬元,已結(jié)題,主持
、 學(xué)術(shù)成果(以下為本人作為主要作者的近5年SCI/中文核心)
1) Liu Z, Zhang Y, Ma N, Yang Y, Ma Y, Wang F, Wang Y, Wei J, Chen H, Tartarone A, Velotta JB, Dayyani F, Gabriel E, Wakefield CJ, Kidane B, Carbonelli C, Long L, Liu Z, Su J, Li Zhigang*. Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell. 2023.(代表作,首個針對新輔助免疫化療主流治療模式下食管鱗癌免疫治療響應(yīng)分子機制與生物標志物的探索研究)
2) Du Y, Shi J, Wang J, Xun Z, Yu Z, Sun H, Bao R, Zheng J, Li Zhigang*, Ye Y. Integration of Pan-Cancer Single-Cell and Spatial Transcriptomics Reveals Stromal Cell Features and Therapeutic Targets in Tumor Microenvironment. Cancer Res. 2023.
3) Ma N, Hua R, Yang Y, Liu ZC, Pan J, Yu BY, Sun YF, Xie D, Wang Y, Li Zhigang*. PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. J Biomed Sci. 2023.
4) Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li C, Li Zhigang*. Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2023. (代表作,首個提供有關(guān)新輔助免疫治療生存數(shù)據(jù)的最大樣本量臨床試驗結(jié)果)
5) Tang R, Liang H, Guo Y, Li Zhigang*, Liu Z, Lin X, Yan Z, Liu J, Xu X, Shao W, Li S, Liang W, Wang W, Cui F, He H, Yang C, Jiang L, Wang H, Chen H, Guo C, Zhang H, Gao Z, He Y, Chen X, Zhao L, Yu H, Hu J, Zhao J, Li B, Yin C, Mao W, Lin W, Xie Y, Liu J, Li X, Wu D, Hou Q, Chen Y, Chen D, Xue Y, Liang Y, Tang W, Wang Q, Li E, Liu H, Wang G, Yu P, Chen C, Zheng B, Chen H, Zhang Z, Wang L, Wang A, Li Z, Fu J, Zhang G, Zhang J, Liu B, Zhao J, Deng B, Han Y, Leng X, Li Z, Zhang M, Liu C, Wang T, Luo Z, Yang C, Guo X, Ma K, Wang L, Jiang W, Han X, Wang Q, Qiao K, Xia Z, Zheng S, Xu C, Peng J, Wu S, Zhang Z, Huang H, Pang D, Liu Q, Li J, Ding X, Liu X, Zhong L, Lu Y, Xu F, Dai Q, He J. Pan-mediastinal neoplasm diagnosis via nationwide federated learning: a multicentre cohort study. Lancet Digit Health. 2023.
6) Yang Y, Liu Z, Jiang C, Pan J, Yu B, Zhu K, Xu Y, Li Zhigang*. Prognostic Value of Combination of Lymphocyte-to-Monocyte-Ratio and CYFRA 21-1 in Esophageal Squamous Cell Carcinoma. World J Surg. 2023.
7) Yang Y, Li B, Xu X, Liu Z, Jiang C, Wu X, Yang Y, Li Zhigang*. Short-term and long-term effects of recurrent laryngeal nerve injury after robotic esophagectomy. Eur J Surg Oncol. 2023.
8) Pan J, Liu Z, Yang Y, Li B, Hua R, Guo X, Sun Y, Li C, Li Zhigang*. Salvage Esophagectomy After Definitive Chemoradiotherapy for Squamous Cell Esophageal Cancer: A Propensity Score Matching Study in a High-Volume Center. World J Surg. 2023.
9) Xu S, Chen D, Liu Z, Song P, Zheng Y, Xue X, Sang Y, Li Zhigang*, Chen Y. Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study. Eur J Cardiothorac Surg. 2023.
10) Jiang H, Guo X, Sun Y, Hua R, Li B, Li Zhigang*. Robot-assisted versus thoracolaparoscopic oesophagectomy for locally advanced oesophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Eur J Surg Oncol. 2023.
11) Zhang L, Yu B, Liu Z, Wei J, Pan J, Jiang C, Li Zhigang*. Analysis of the Clinicopathological Characteristics, Prognosis, and Lymphocyte Infiltration of Esophageal Neuroendocrine Neoplasms: A Surgery-Based Cohort and Propensity-Score Matching Study. Cancers. 2023.
12) Li C, Li B, Yang Y, Li Zhigang*. Short-term clinical effects of robot-assisted esophagectomy with thoracic duct resection. J Gastrointest Oncol. 2023.
13) Li C, Zhu M, Lu Q, Yu B, Yang Y, Li B, Peng Z, Li Zhigang*. Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic efficacy in esophageal cancer. Ann Transl Med. 2023.
14) Yang Y, Zhang H, Liu Z, Ma N, Li C, Wang Y, Li Zhigang*. Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy. Ann Transl Med. 2023.
15) Yang Y, Li B, Yi J, Hua R, Chen H, Tan L, Li H, He Y, Guo X, Sun Y, Yu B, Li Zhigang*. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial. Ann Surg. 2022.(代表作,國際首個III期RCT確立機器人輔助食管癌根治術(shù)是一種安全有效的手術(shù)方式,為機器人微創(chuàng)外科發(fā)展提供了重要佐證)
16) Yang Y, Zhang H, Li B, Shao J, Liu Z, Hua R, Li Zhigang*. Patterns of recurrence after robot-assisted minimally invasive esophagectomy in esophageal squamous cell carcinoma. Semin Thorac Cardiovasc Surg. 2022.
17) Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li Zhigang*. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022.(代表作,率先開展臨床試驗證明新輔助免疫治療能夠明顯提升食管癌的腫瘤退縮效果且安全性可靠,為食管癌新輔助治療提供了新選擇)
18) Yang Y, Tan L, Hu J, Li Y, Mao Y, Tian Z, Zhang B, Ma J, Li H, Chen C, Chen K, Han Y, Chen L, Liu J, Yu B, Yu Z, Li Zhigang*. Esophageal Cancer Committee of Chinese Anti-Cancer Association. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China. Dis Esophagus. 2022.(代表作,牽頭開展中國新輔助免疫治療的真實世界研究結(jié)果,推動 CSCO食管癌診療指南將“食管癌新輔助免疫治療”方案納入推薦。)
19) Liu Z, Liu J, Li Zhigang*. Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations. Signal Transduct Target Ther. 2022.
20) Ko JM, Guo C, Liu C, Ning L, Dai W, Tao L, Lo AW, Wong CW, Wong IY, Chan FS, Wong CL, Chan KK, Law TT, Lee NP, Liu Z, Jiang H, Li Zhigang*, Law S, Lung ML. Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma. Br J Cancer. 2022.
21) Huang B, Deng Y, Liu Z, Zhu X, Su Y, Gu D, Li Zhigang*, Fang W, Pennathur A, Luketich JD, Xiang J, Chen H, Wu Q, Xu W, Zhang J. Oesophagectomy following noncurative endoscopic resection for oesophageal carcinoma: does interval matter? Eur J Cardiothorac Surg. 2022.
22) Yang Y, Zhu L, Cheng Y, Liu Z, Cai X, Shao J, Zhang M, Liu J, Sun Y, Li Y, Yi J, Yu B, Jiang H, Chen H, Yang H, Tan L, Li Zhigang*. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study). BMC Cancer. 2022.
23) Yang Y, Liu Z, Sun Y, Guo X, Li B, Hua R, Yang Y, Mao T, Zhang H, Su Y, Li C, Li Zhigang*. Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment in Shanghai Chest Hospital, 2016. J Thorac Dis. 2022.
24) Li C, Li B, Yang Y, Liu J, Zhang M, Zhang H, Tan L, Shen X, Li Zhigang*. Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC). J Thorac Dis. 2022.
25) Zhang L, Shao J, Liu Z, Pan J, Li B, Yang Y, He Y, Han Y, Li Zhigang*. Occurrence and Prognostic Value of Perineural Invasion in Esophageal Squamous Cell Cancer: A Retrospective Study. Ann Surg Oncol. 2022.
26) He Y, Hua R, Yang Y, Li B, Guo X, Li Zhigang*. LncRNA JPX Promotes Esophageal Squamous Cell Carcinoma Progression by Targeting miR-516b-5p/VEGFA Axis. Cancers. 2022.
27) 李志剛.頸段食管癌挽救性切除的核心技術(shù):從全喉下咽聯(lián)合切除到縱隔氣管造口[J].中華消化外科雜志, 2022.
28) 李志剛.免疫新時代食管癌按需治療關(guān)鍵問題及策略[J].中華消化外科雜志, 2022.
29) Ye B, Fan D, Xiong W, Li M, Yuan J, Jiang Q, Zhao Y, Lin J, Liu J, Lv Y, Wang X, Li Zhigang*, Su J, Qiao Y. Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis. Nat Commun. 2021.
30) Jiang H, Hua R, Sun Y, Guo X, Liu Z, Su Y, Li B, Yang Y, Zhang H, Li Zhigang*. Risk Factors for Anastomotic Complications After Radical McKeown Esophagectomy. Ann Thorac Surg. 2021.
31) Yang Y, Li B, Hua R, Zhang X, Jiang H, Sun Y, Veronesi G, Ricciardi S, Casiraghi M, Durand M, Caso R, Sarkaria IS, Li Zhigang*; Written on behalf of the AME Thoracic Surgery Collaborative Group. Assessment of Quality Outcomes and Learning Curve for Robot-Assisted Minimally Invasive McKeown Esophagectomy. Ann Surg Oncol. 2021.
32) Liu Z, Zhang J, Su Y, Pan J, Yang Y, Huang B, Zhao J, Li Zhigang*. Additional Esophagectomy Following Noncurative Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study. Ann Surg Oncol. 2021.
33) Ye B, Zhang X, Su Y, Hao S, Teng H, Guo X, Yang Y, Sun Y, Mao T, Li Zhigang*. The possibility of endoscopic treatment of cN0 submucosal esophageal cancer: results from a surgic
24年10月底來治療,李主任給出方案,放化免同步新輔助治療,...
2004年寒冬臘月,命運給了我沉重一擊——12月22日體檢報...
病情描述:我母親感覺氣不好喘,容易疲勞,想睡覺。在當(dāng)?shù)蒯t(yī)院檢...